GREENLAND MINES LTD Increase (Decrease) in Derivative Liabilities
GREENLAND MINES LTD (GRML) reported Increase (Decrease) in Derivative Liabilities of $10.60 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2023-10-18
- GREENLAND MINES LTD increase (decrease) in derivative liabilities for the quarter ending 2023-03-31 was $10.60K.
- GREENLAND MINES LTD increase (decrease) in derivative liabilities for the quarter ending 2022-12-31 was $0.00.
- GREENLAND MINES LTD increase (decrease) in derivative liabilities for fiscal 2022 was -$555.92K.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month | Increase (Decrease) in Derivative Liabilities 9 month | Increase (Decrease) in Derivative Liabilities 12 month |
|---|---|---|---|---|
| 2023-03-31 | $10.60K 10-Q · filed 2023-05-24 | $10.60K derived: sum of 2 quarters · filed 2023-10-18 | ||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-10-18 | -$555.92K 10-K/A · filed 2023-10-18 | ||
| 2022-09-30 | -$555.92K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |